Oncology · Colorectal CancerTrial Updateclinicalmid-term

Phase I/II Trial of STAR15 Combination Therapy for Metastatic Colorectal Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 12:31:55 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I/II trial of the STAR15 combination therapy represents a significant advancement in the treatment landscape for metastatic colorectal cancer. The results could reshape treatment protocols and influence competitive dynamics among companies developing therapies in this space. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 11 ranked evidence items (5 high-relevance).

Strategic Assessment

The outcomes of this trial may influence future treatment protocols and competitive positioning for companies involved in colorectal cancer therapies. The strongest clinical anchor is Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (ClinicalTrials.gov), entity match (national cancer institute). In colorectal cancer, 3 regulatory and 1 competitive items passed relevance filtering for retifanlimab.

Competitive Pressure

The most relevant competitive pressure comes from City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection (Humanexa Signals) — sub-indication match (colorectal cancer). This trial introduces a novel combination therapy that could enhance treatment options in a competitive oncology landscape, particularly for mCRC.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Entity match (retifanlimab). Relevant agencies in corpus: MHRA, FDA. The trial's results may inform future regulatory submissions and approvals, impacting the labeling and market entry of these combination therapies.

Key Risks

Elevated medium regulatory exposure for retifanlimab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful outcomes from this trial could enhance market share for the involved therapies, potentially leading to increased revenue streams for companies that can capitalize on improved treatment options.
Upside for retifanlimab may improve if Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
The outcomes of this trial may influence future treatment protocols and competitive positioning for companies involved in colorectal cancer therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and patient response rates, as well as any announcements regarding further development or partnerships.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Entity match (retifanlimab)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection
Humanexa Signalsmedium relevance
Sub-indication match (colorectal cancer)
Phase I/II Trial of Iberdomide in Relapsed Neuroblastoma Shows Potential Efficacy
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Patient population match (metastatic)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Patient population match (metastatic)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

retifanlimab
National Cancer Institute
TriAdeno vaccine

Commercial impact

medium

Successful outcomes from this trial could enhance market share for the involved therapies, potentially leading to increased revenue streams for companies that can capitalize on improved treatment options.

Regulatory impact

medium

The trial's results may inform future regulatory submissions and approvals, impacting the labeling and market entry of these combination therapies.

What to watch

Monitor trial results and patient response rates, as well as any announcements regarding further development or partnerships.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.